Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
Healthcare
$9.13 +0.66%
+$0.13 today
- Market cap
- $821.96M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
52W Low $8.59High $25.59
Volume 3.30M
Average 1.70M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$322.98M
FY 2025 · Annual
Investing Cash Flow
$290.04M
FY 2025 · Annual
Financing Cash Flow
$13.68M
FY 2025 · Annual
-96.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$285.4M
+ D&A$6.0K
+ Stock-Based Comp$47.5M
+ Deferred Tax$0
- Working Capital-$79.3M
- Other Non-Cash-$5.7M
= Operating Cash Flow-$323.0M
- Capex-$187.0K
= Free Cash Flow-$323.2M
Analysis
FY2025 free cash flow is -$323.2M. FCF conversion is 113.2% of net income. Operating cash flow was -$323.0M, with capex of -$187.0K. The largest bridge item is Working Capital at -$79.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 2, 2026 | |
| 8-K | Current report | Nov 2, 2026 |
Does SNDX generate free cash flow?
Syndax Pharmaceuticals, Inc. (SNDX) generated -$323.17M of free cash flow in fiscal 2025.
How much operating cash flow does SNDX produce?
Operating cash flow was -$322.98M, before capital expenditures of $187,000.00.
Continue the stock analysis
Jump to another research area for this company.